At Business Growth Point, we focus on what really matters — practical strategies, real-world examples, and proven tactics to grow your business.
Regeneron Pharmaceuticals has agreed to acquire the bankrupt genetic testing company 23andMe for $256 million, marking a significant shift in the consumer genomics landscape.
The deal, expected to close in the third quarter of 2025 pending court and regulatory approvals, includes 23andMe’s core assets: its Personal Genome Service, Total Health and Research Services, and a biobank containing genetic data from over 15 million users. Notably, the acquisition excludes 23andMe’s telehealth service, Lemonaid Health, which will be discontinued
Regeneron has pledged to uphold 23andMe’s existing privacy policies and comply with applicable laws to protect user genetic data. To address privacy concerns, the company will work with an independent, court-appointed customer-privacy ombudsman to ensure ethical data handling .
The acquisition follows 23andMe’s Chapter 11 bankruptcy filing in March 2025, which came after a series of setbacks, including a major data breach in 2023 that affected nearly 7 million users and a significant workforce reduction of about 40%. Co-founder Anne Wojcicki also resigned as CEO after her acquisition proposal was rejected by the company’s Special Committee .
Regeneron intends to continue employing staff from the acquired business units and leverage its data expertise to further both companies’ missions in genetic research and personalized health. The company has a proven track record in protecting genetic data at its genetics center, which it uses to identify genes associated with specific illnesses .
A court hearing to consider the transaction’s approval is scheduled for June 17, 2025
